NCT00002262已完成1 期
A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections. In addition, to assess the effects of TNF injections on Kaposi's sarcoma (KS) lesions as measured by P-32 magnetic resonance spectroscopy.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid TumorsSolid TumorNCT06368921Guangzhou Virotech Pharmaceutical Co., Ltd.30
终止
1 期
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)Neoplasm MetastasisNCT04521621Merck Sharp & Dohme LLC76
招募中
2 期
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsCarcinoma, Basal CellCarcinoma, Cutaneous Squamous CellNCT04362722Philogen S.p.A.40
撤回
1 期
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the BladderMuscle-invasive Transitional Cell Carcinoma of the BladderNCT02723838Oncolytics Biotech
已完成
1 期
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM PatientsGlioblastomaNCT02869243Stemgen15